Starpharma Holdings Limited (SPHRF)
USD 0.06
(7.53%)
USD 0.06
(7.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 3.52 Million AUD | -57.35% |
| 2023 | 8.27 Million AUD | 1.01% |
| 2022 | 8.18 Million AUD | 601.71% |
| 2021 | 1.16 Million AUD | -25.86% |
| 2020 | 1.57 Million AUD | 5953.85% |
| 2019 | 26 Thousand AUD | -46.94% |
| 2018 | 49 Thousand AUD | -30.0% |
| 2017 | 70 Thousand AUD | 288.89% |
| 2016 | 18 Thousand AUD | -62.5% |
| 2015 | 48 Thousand AUD | -36.0% |
| 2014 | 75 Thousand AUD | -25.0% |
| 2013 | 100 Thousand AUD | -28.57% |
| 2012 | 140 Thousand AUD | 112.12% |
| 2011 | 66 Thousand AUD | -58.75% |
| 2010 | 160 Thousand AUD | -45.39% |
| 2009 | 293 Thousand AUD | -29.74% |
| 2008 | 417 Thousand AUD | 26.85% |
| 2007 | 328.73 Thousand AUD | -28.15% |
| 2006 | 457.5 Thousand AUD | 227.36% |
| 2005 | 139.75 Thousand AUD | -31.33% |
| 2004 | 203.52 Thousand AUD | -22.77% |
| 2003 | 263.52 Thousand AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 775 Thousand AUD | -75.23% |
| 2024 Q4 | 3.52 Million AUD | 355.23% |
| 2024 FY | 3.52 Million AUD | -57.35% |
| 2024 Q1 | 2.35 Million AUD | -71.19% |
| 2024 Q2 | 3.12 Million AUD | 32.64% |
| 2023 Q1 | 7.13 Million AUD | -12.93% |
| 2023 FY | 8.27 Million AUD | 1.01% |
| 2023 Q4 | 8.18 Million AUD | 8.78% |
| 2023 Q3 | 7.52 Million AUD | -4.09% |
| 2023 Q2 | 7.84 Million AUD | 10.08% |
| 2022 FY | 8.18 Million AUD | 601.71% |
| 2022 Q4 | 8.18 Million AUD | 9.27% |
| 2022 Q2 | 3.7 Million AUD | 27.26% |
| 2022 Q3 | 7.49 Million AUD | 102.16% |
| 2022 Q1 | 2.91 Million AUD | 149.61% |
| 2021 Q2 | 1.49 Million AUD | 80.58% |
| 2021 Q1 | 829 Thousand AUD | -47.33% |
| 2021 Q3 | 475 Thousand AUD | -68.27% |
| 2021 Q4 | 1.16 Million AUD | 145.68% |
| 2021 FY | 1.16 Million AUD | -25.86% |
| 2020 Q2 | 1.87 Million AUD | 46.33% |
| 2020 Q1 | 1.28 Million AUD | 4823.08% |
| 2020 FY | 1.57 Million AUD | 5953.85% |
| 2020 Q4 | 1.57 Million AUD | 62.27% |
| 2020 Q3 | 970 Thousand AUD | -48.21% |
| 2019 Q1 | 11 Thousand AUD | -77.55% |
| 2019 FY | 26 Thousand AUD | -46.94% |
| 2019 Q2 | 11 Thousand AUD | 0.0% |
| 2019 Q3 | - AUD | -100.0% |
| 2019 Q4 | 26 Thousand AUD | 0.0% |
| 2018 Q2 | 36 Thousand AUD | 0.0% |
| 2018 FY | 49 Thousand AUD | -30.0% |
| 2018 Q4 | 49 Thousand AUD | 113.04% |
| 2018 Q1 | 36 Thousand AUD | -48.57% |
| 2018 Q3 | 23 Thousand AUD | -36.11% |
| 2017 Q3 | 47 Thousand AUD | 0.0% |
| 2017 FY | 70 Thousand AUD | 288.89% |
| 2017 Q1 | - AUD | -100.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q4 | 70 Thousand AUD | 48.94% |
| 2016 Q1 | 3000.00 AUD | -93.75% |
| 2016 Q4 | 18 Thousand AUD | 0.0% |
| 2016 Q2 | 3000.00 AUD | 0.0% |
| 2016 Q3 | - AUD | -100.0% |
| 2016 FY | 18 Thousand AUD | -62.5% |
| 2015 FY | 48 Thousand AUD | -36.0% |
| 2015 Q2 | 33 Thousand AUD | 0.0% |
| 2015 Q4 | 48 Thousand AUD | 166.67% |
| 2015 Q3 | 18 Thousand AUD | -45.45% |
| 2015 Q1 | 33 Thousand AUD | -56.0% |
| 2014 Q3 | 48 Thousand AUD | -22.58% |
| 2014 Q1 | 62 Thousand AUD | -38.0% |
| 2014 FY | 75 Thousand AUD | -25.0% |
| 2014 Q4 | 75 Thousand AUD | 56.25% |
| 2014 Q2 | 62 Thousand AUD | 0.0% |
| 2013 Q3 | 75 Thousand AUD | 0.0% |
| 2013 Q4 | 100 Thousand AUD | 33.33% |
| 2013 FY | 100 Thousand AUD | -28.57% |
| 2013 Q1 | - AUD | -100.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2012 FY | 140 Thousand AUD | 112.12% |
| 2012 Q4 | 140 Thousand AUD | 0.0% |
| 2011 FY | 66 Thousand AUD | -58.75% |
| 2011 Q4 | 66 Thousand AUD | 0.0% |
| 2010 Q4 | 160 Thousand AUD | 0.0% |
| 2010 FY | 160 Thousand AUD | -45.39% |
| 2009 Q4 | 293 Thousand AUD | 0.0% |
| 2009 FY | 293 Thousand AUD | -29.74% |
| 2008 FY | 417 Thousand AUD | 26.85% |
| 2008 Q4 | 417 Thousand AUD | 0.0% |
| 2007 FY | 328.73 Thousand AUD | -28.15% |
| 2007 Q4 | 328.73 Thousand AUD | 0.0% |
| 2006 Q4 | 457.5 Thousand AUD | 0.0% |
| 2006 FY | 457.5 Thousand AUD | 227.36% |
| 2005 FY | 139.75 Thousand AUD | -31.33% |
| 2005 Q4 | 139.75 Thousand AUD | 0.0% |
| 2004 Q4 | 203.52 Thousand AUD | 0.0% |
| 2004 FY | 203.52 Thousand AUD | -22.77% |
| 2003 FY | 263.52 Thousand AUD | 0.0% |
| 2003 Q4 | 263.52 Thousand AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -83.273% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 91.438% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -777.942% |
| SQZ Biotechnologies Company | 27.47 Million USD | 87.157% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -51.68% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 91.866% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 88.148% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -272.046% |
| Marizyme, Inc. | 18.71 Million USD | 81.151% |
| Genus plc | 233.1 Million USD | 98.486% |
| Pharming Group N.V. | 171.54 Million USD | 97.943% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -297.269% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -162.581% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -370.4% |
| ContraFect Corporation | 2.88 Million USD | -22.457% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -143.93% |
| IMV Inc. | 28.88 Million USD | 87.786% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 37.65% |
| ONE Bio Corp. | 19.71 Million USD | 82.105% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 93.863% |
| Mesoblast Limited | 118.7 Million USD | 97.028% |
| MultiCell Technologies, Inc. | 202.58 USD | -1741434.209% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 89.342% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.155% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -459.932% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -187.212% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 14.41% |
| Biomind Labs Inc. | 735.54 Thousand USD | -379.646% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -16.582% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 72.855% |
| Skye Bioscience, Inc. | 4.61 Million USD | 23.558% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -880.79% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -20.394% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2392.969% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2503.94% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 39.909% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -13617.485% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -136.026% |
| Q BioMed Inc. | 4.1 Million USD | 14.16% |
| GB Sciences, Inc. | 1.75 Million USD | -100.534% |
| Alpha Cognition Inc. | 1.22 Million USD | -189.092% |
| CSL Limited | 12.18 Billion USD | 99.971% |
| Agentix Corp. | 50 Thousand USD | -6956.0% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 94.784% |
| Enzolytics Inc. | 996.33 Thousand USD | -254.097% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | 45.648% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1280.325% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -56.218% |
| argenx SE | 20 Million USD | 82.36% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 92.256% |
| HST Global, Inc. | 98.31 Thousand USD | -3488.32% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1318.463% |
| Halberd Corporation | 150 Thousand USD | -2252.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 50.119% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -34403.667% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -30.247% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -47.14% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1438.656% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2273.296% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1658.584% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -60.372% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 82.645% |
| Kadimastem Ltd | 891.22 Thousand USD | -295.859% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 25.118% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1310.173% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -10398.125% |
| Cell Source, Inc. | 9.25 Million USD | 61.877% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -366.541% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -366.541% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -628.498% |
| Itoco Inc. | 228.37 Thousand USD | -1444.814% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1572.236% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 29.199% |
| International Stem Cell Corporation | 4.17 Million USD | 15.558% |
| CytoDyn Inc. | 30.07 Million USD | 88.27% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -902.709% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 54.885% |
| SYBLEU INC | 477.5 Thousand USD | -638.848% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2780.0% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1038.065% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 25.495% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -5552.669% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -61.768% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 57.576% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 58.905% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -126.811% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1216.418% |
| Neutra Corp. | 54.15 Thousand USD | -6414.514% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -92.787% |
| PureTech Health plc | 25.51 Million USD | 86.171% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -188.182% |
| IXICO plc | 472.02 Thousand USD | -647.421% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 77.24% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 94.334% |
| CSL Limited | 12.18 Billion USD | 99.971% |
| Cellectis S.A. | 92.77 Million USD | 96.197% |